Lotus Pharma Unit to License Two Alvotech Biosimilars in $150 Million Deal

MT Newswires Live

Aug 24

Lotus Pharmaceutical's (TPE:1795) subsidiary, Lotus International, has agreed to acquire licensing rights to two early-stage biosimilar candidates from Alvotech in a deal worth up to $150 million, according to a Friday filing with the Taiwan Stock Exchange.

The agreement for Durvalumab and Emicizumab grants Lotus semi-exclusive rights in the US and exclusive rights across several Asia-Pacific markets.

Consideration includes up to $5 million in combined upfront payments alongside milestone payments totaling up to $144.1 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/news/2661228217"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661228217\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661228217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-24 13:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661228217","market":"us","top_or_hot":-1,"title":"Lotus Pharma Unit to License Two Alvotech Biosimilars in $150 Million Deal","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LOT\">Lotus</a> Pharmaceutical's (TPE:1795) subsidiary, Lotus International, has agreed to acquire licensing rights to two early-stage biosimilar candidates from <a href=\"https://laohu8.com/S/ALVO\">Alvotech</a> in a deal worth up to $150 million, according to a Friday filing with the Taiwan Stock Exchange.</p><p>The agreement for Durvalumab and Emicizumab grants Lotus semi-exclusive rights in the US and exclusive rights across several Asia-Pacific markets.</p><p>Consideration includes up to $5 million in combined upfront payments alongside milestone payments totaling up to $144.1 million.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lotus Pharma Unit to License Two Alvotech Biosimilars in $150 Million Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLotus Pharma Unit to License Two Alvotech Biosimilars in $150 Million Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-24 13:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LOT\">Lotus</a> Pharmaceutical's (TPE:1795) subsidiary, Lotus International, has agreed to acquire licensing rights to two early-stage biosimilar candidates from <a href=\"https://laohu8.com/S/ALVO\">Alvotech</a> in a deal worth up to $150 million, according to a Friday filing with the Taiwan Stock Exchange.</p><p>The agreement for Durvalumab and Emicizumab grants Lotus semi-exclusive rights in the US and exclusive rights across several Asia-Pacific markets.</p><p>Consideration includes up to $5 million in combined upfront payments alongside milestone payments totaling up to $144.1 million.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALVO","symbol_name":"Alvotech","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2661228217","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661228217","pubTimestamp":1787548950,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lotus Pharmaceutical's (TPE:1795) subsidiary, Lotus International, has agreed to acquire licensing rights to two early-stage biosimilar candidates from Alvotech in a deal worth up to $150 million, acc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALVO":"Alvotech","BK4139":"生物科技"},"translate_title":"Lotus Pharma 子公司将以 1.5 亿美元的价格授权两种 Alvotech 生物仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVO":1.5},"content_text":"Lotus Pharmaceutical's (TPE:1795) subsidiary, Lotus International, has agreed to acquire licensing rights to two early-stage biosimilar candidates from Alvotech in a deal worth up to $150 million, according to a Friday filing with the Taiwan Stock Exchange.The agreement for Durvalumab and Emicizumab grants Lotus semi-exclusive rights in the US and exclusive rights across several Asia-Pacific markets.Consideration includes up to $5 million in combined upfront payments alongside milestone payments totaling up to $144.1 million.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}